High-Resolution Diffusion-Weighted Imaging for Monitoring Breast Cancer Treatment Response

Rationale and Objectives The aim of this work was to compare a high-resolution diffusion-weighted imaging (HR-DWI) acquisition (voxel size = 4.8 mm3 ) to a standard diffusion-weighted imaging (STD-DWI) acquisition (voxel size = 29.3 mm3 ) for monitoring neoadjuvant therapy-induced changes in breast...

Full description

Saved in:
Bibliographic Details
Published in:Academic radiology Vol. 20; no. 5; pp. 581 - 589
Main Authors: Wilmes, Lisa J., PhD, McLaughlin, Rebekah L., MPhil, Newitt, David C., PhD, Singer, Lisa, PhD, Sinha, Sumedha P., PhD, Proctor, Evelyn, BS, Wisner, Dorota J., MD, PhD, Saritas, Emine U., PhD, Kornak, John, PhD, Shankaranarayanan, Ajit, PhD, Banerjee, Suchandrima, PhD, Jones, Ella F., PhD, Joe, Bonnie N., MD, PhD, Hylton, Nola M., PhD
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01-05-2013
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale and Objectives The aim of this work was to compare a high-resolution diffusion-weighted imaging (HR-DWI) acquisition (voxel size = 4.8 mm3 ) to a standard diffusion-weighted imaging (STD-DWI) acquisition (voxel size = 29.3 mm3 ) for monitoring neoadjuvant therapy-induced changes in breast tumors. Materials and Methods Nine women with locally advanced breast cancer were imaged with both HR-DWI and STD-DWI before and after 3 weeks (early treatment) of neoadjuvant taxane-based treatment. Tumor apparent diffusion coefficient (ADC) metrics (mean and histogram percentiles) from both DWI methods were calculated, and their relationship to tumor volume change after 12 weeks of treatment (posttreatment) measured by dynamic contrast enhanced magnetic resonance imaging was evaluated with a Spearman's rank correlation. Results The HR-DWI pretreatment 15th percentile tumor ADC ( P  = .03) and early treatment 15th, 25th, and 50th percentile tumor ADCs ( P  = .008, .010, .04, respectively) were significantly lower than the corresponding STD-DWI percentile ADCs. The mean tumor HR-ADC was significantly lower than STD-ADC at the early treatment time point ( P = .02), but not at the pretreatment time point ( P = .07). A significant early treatment increase in tumor ADC was found with both methods ( P < .05). Correlations between HR-DWI tumor ADC and posttreatment tumor volume change were higher than the STD-DWI correlations at both time points and the lower percentile ADCs had the strongest correlations. Conclusion These initial results suggest that the HR-DWI technique has potential for improving characterization of low tumor ADC values over STD-DWI and that HR-DWI may be of value in evaluating tumor change with treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1076-6332
1878-4046
DOI:10.1016/j.acra.2013.01.009